Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) will likely be releasing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Crinetics Pharmaceuticals to post earnings of ($1.35) per share and revenue of $4.3230 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals Stock Down 0.5%

Shares of CRNX stock opened at $43.45 on Thursday. The firm’s 50 day moving average price is $49.52 and its two-hundred day moving average price is $42.46. Crinetics Pharmaceuticals has a fifty-two week low of $24.10 and a fifty-two week high of $57.99. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of -9.59 and a beta of 0.19.

Analysts Set New Price Targets

CRNX has been the topic of a number of recent research reports. The Goldman Sachs Group upgraded Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price objective on the stock in a research note on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, January 21st. Lifesci Capital upgraded shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a research note on Friday, February 13th. Wall Street Zen downgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Finally, Citizens Jmp decreased their price objective on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating for the company in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $75.78.

Insider Buying and Selling at Crinetics Pharmaceuticals

In related news, insider Isabel Kalofonos sold 2,500 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $55.00, for a total value of $137,500.00. Following the completion of the transaction, the insider directly owned 834 shares in the company, valued at approximately $45,870. This trade represents a 74.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.60% of the company’s stock.

Institutional Trading of Crinetics Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Crinetics Pharmaceuticals by 11.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company’s stock worth $1,995,000 after buying an additional 6,148 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Crinetics Pharmaceuticals by 6.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company’s stock worth $11,658,000 after acquiring an additional 22,305 shares during the period. Strs Ohio acquired a new position in shares of Crinetics Pharmaceuticals during the first quarter valued at $124,000. Invesco Ltd. raised its stake in shares of Crinetics Pharmaceuticals by 11.7% during the second quarter. Invesco Ltd. now owns 78,140 shares of the company’s stock valued at $2,247,000 after purchasing an additional 8,181 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Crinetics Pharmaceuticals by 20.6% during the second quarter. Sei Investments Co. now owns 60,180 shares of the company’s stock valued at $1,731,000 after purchasing an additional 10,269 shares in the last quarter. Institutional investors own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.